comprehensive -WSS

comprehensive

author：explore 2025-09-29 22:48:41 - browse：525

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

WSS

Tome Biosciences co

It's been 20 years since Dolly the sheep. Where's my clone?

Why Eli Lilly’s earnings didn’t quite live up to the hype

STAT Virtual Event: Putting AI to the Test

Thermo Fisher plant for manufacturing gene therapies to expand

CommonSpirit Health keeps growing, even as it loses money

entertainment

comprehensive

hotspot

Alkermes shareholders re

Latigo launches with $135 million for Vertex

As demand for Covid shots wanes, Moderna seeks its next success

CommonSpirit Health keeps growing, even as it loses money

Anesthesiologist group: stop taking Ozempic before surgery

Hearing on Medicare drug price negotiation gets unusually heated

Heart attack and stroke risk calculators need revising

Drug for rare kidney disease narrowly misses mark in clinical trial

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why Eli Lilly’s earnings didn’t quite live up to the hype

entertainment

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress might make insulin pumps more accessible to the blind

EpiPen alternative approval delay highlights citizen petition issue

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Readout LOUD podcast: possible new ALS drug, artificial wombs

Why don't Americans have at

Wikipedia

explore

focus

entertainment